Aqueous humor sCD44 concentration and visual field loss in primary open-angle glaucoma

Journal of Glaucoma

Volumn 16, Issue 5, 2007, Pages 419-429

  Nolan, Michael J ^a   Giovingo, Michael C ^a   Miller, Adam M ^a   Wertz, Robert D ^b   Ritch, Robert ^c   Liebmann, Jeffrey M ^c   Rand Allingham, R ^d   Herndon, Leon W ^d   Wax, Martin B ^e,f   Smolyak, Regina ^e   Hasan, Fareed ^e   Barnett, Edward M ^e   Samples, John R ^g   Knepper, Paul A ^a,b,h  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

^c NEW YORK EYE AND EAR INFIRMARY   (United States)

^d DUKE UNIVERSITY EYE CENTER   (United States)

^e WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f ALCON RESEARCH LTD   (United States)

^g or 97239 4197   (United States)

^h NONE   (United States)

Author keywords

CD44; Glaucoma; Risk factors; Visual fields

Indexed keywords

ALPHA ADRENERGIC RECEPTOR STIMULATING AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARBONATE DEHYDRATASE INHIBITOR; HERMES ANTIGEN; PILOCARPINE; PROSTAGLANDIN DERIVATIVE;

ADULT; AGED; ANALYSIS OF VARIANCE; ARTICLE; CATARACT EXTRACTION; CLINICAL FEATURE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FILTERING OPERATION; GROUPS BY AGE; HUMAN; INTRAOCULAR PRESSURE; MAJOR CLINICAL STUDY; OPEN ANGLE GLAUCOMA; PRIORITY JOURNAL; RACE DIFFERENCE; RISK FACTOR; SEX DIFFERENCE; TRABECULOPLASTY; VISUAL FIELD; VISUAL FIELD DEFECT;

ADULT; AFRICAN AMERICANS; AGED; AGED, 80 AND OVER; ANTIGENS, CD44; ANTIHYPERTENSIVE AGENTS; AQUEOUS HUMOR; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; ENZYME-LINKED IMMUNOSORBENT ASSAY; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; GLAUCOMA, OPEN-ANGLE; HUMANS; INTRAOCULAR PRESSURE; MALE; MIDDLE AGED; RISK FACTORS; SOLUBILITY; VISION DISORDERS; VISUAL FIELDS;

EID: 34547912469     PISSN: 10570829     EISSN: None     Source Type: Journal    
DOI: 10.1097/IJG.0b013e318050ab4b     Document Type: Article

References (67)

1. Coleman AL. Glaucoma. Lancet. 1999;354:1803-1810.
2. Fan BJ, Wang DY, Lam DS, et al. Gene mapping for primary open angle glaucoma. Clin Biochem. 2006;39:249-258.
3. Muchowski PJ, Wacker JL. Modulation of neurodegeneration by molecular chaperones. Nat Rev Neurosci. 2005;6:11-22.
4. Weinreb RN, Khaw PT. Primary open-angle glaucoma. Lancet. 2004;363:1711-1720.
5. Gordon MO, Beiser JA, Brandt JD, et al. The Ocular Hypertension Treatment Study: baseline factors that predict the onset of primary open-angle glaucoma. Arch Ophthalmol. 2002;120:714-720.
6. Liesegang TJ. Glaucoma: changing concepts and future directions. Mayo Clin Proc. 1996;71:689-694.
7. Krupin T, Liebmann JM, Greenfield DS, et al. Low-Pressure Glaucoma Study Group. The Low-pressure Glaucoma Treatment Study (LoGTS) study design and baseline characteristics of enrolled patients. Ophthalmology. 2005;112:376-385.
8. Racette L, Wilson MR, Zangwill LM, et al. Primary open-angle glaucoma in blacks: a review. Surv Ophthalmol. 2003;8:295-313.
9. Higginbotham EJ, Gordon MO, Beiser JA, et al. Ocular Hypertension Treatment Study Group. The Ocular Hypertension Treatment Study: topical medication delays or prevents primary open-angle glaucoma in African American individuals. Arch Ophthalmol. 2004;122:813-820.
10. The AGIS Investigators. The Advanced Glaucoma Intervention Study (AGIS): 7. The relationship between control of intraocular pressure and visual field deterioration. Am J Ophthalmol. 2000;130:429-440.
11. Kass MA, Heuer DK, Higginbotham EJ, et al. The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Arch Ophthalmol. 2002;120:701-713.
12. Choi J, Miller AM, Nolan MJ, et al. Soluble CD44 is cytotoxic to trabecular meshwork and retinal ganglion cells in vitro. Invest Ophthalmol Vis Sci. 2005;46:214-222.
13. Cichy J, Pure E. The liberation of CD44. J Cell Biol. 2003;161:839-843.
14. Sherman LS, Rizvi TA, Karyala S, et al. CD44 enhances neuregulin signaling by Schwann cells. J Cell Biol. 2000;150:1071-1083.
15. Bourguignon LY, Singleton PA, Zhu H, et al. Hyaluronan promotes signaling interaction between CD44 and the transforming growth factor beta receptor I in metastatic breast tumor cells. J Biol Chem. 2002;277:39703-39712.
16. Murphy JF, Lennon F, Steele C, et al. Engagement of CD44 modulates cyclooxygenase induction, VEGF generation, and proliferation in human vascular endothelial cells. FASEB. 2005;19:446-448.
17. Okamoto I, Kawano Y, Tsuiki H, et al. CD44 cleavage induced by a membrane-associated metalloprotease plays a critical role in tumor cell migration. Oncogene. 1999;18:1435-1446.
18. Okamoto I, Kawano Y, Murakami D, et al. Proteolytic release of CD44 intracellular domain and its role in the CD44 signaling pathway. J Cell Biol. 2001;155:755-762.
19. Nagano O, Murakami D, Hartmann D, et al. Cell-matrix interaction via CD44 is independently regulated by different metalloproteinases activated in response to extracellular Ca(2+) influx and PKC activation. J Cell Biol. 2004;165:893-902.
20. Stern R, Shuster S, Neudecker BA, et al. Lactate stimulates fibroblast expression of hyaluronan and CD44: the Warburg effect revisited. Exp Cell Res. 2002;276:24-31.
21. Wang H, Zhan Y, Xu L, et al. Use of suppression subtractive hybridization for differential gene expression in stroke: discovery of CD44 gene expression and localization in permanent focal stroke in rats. Stroke. 2001;32:1020-1027.
22. Knepper PA, Miller AM, Choi J, et al. Hypophosphorylation of aqueous humor sCD44 and primary open-angle glaucoma. Invest Ophthalmol Vis Sci. 2005;46:2829-2837.
23. Knepper PA, Goossens W, Mayanil CSK. CD44H localization in primary open-angle glaucoma. Invest Ophthalmol Vis Sci. 1998;39:673-680.
24. Knepper PA, Mayanil CS, Goossens W, et al. Aqueous humor in primary open-angle glaucoma contains an increased level of CD44S. Invest Ophthalmol Vis Sci. 2002;43:133-139.
25. Van Everbroeck B, Quoilin S, Boons J, et al. A prospective study of CSF markers in 250 patients with possible Creutzfeldt-Jakob disease. J Neurol Neurosurg Psychiatry. 2003;74:1210-1214.
26. Clark CM, Xie S, Chittams J, et al. Cerebrospinal fluid tau and betaamyloid: how well do these biomarkers reflect autopsy-confirmed dementia diagnoses? Arch Neurol. 2003;60:1696-1702.
27. Cattabeni F, Colciaghi F, Di Luca M. Platelets provide human tissue to unravel pathogenic mechanisms of Alzheimer disease. Prog Neuropsychopharmacol Biol Psychiatry. 2004;28:763-770.
28. Piemonte F, Pastore A, Tozzi G, et al. Glutathione in blood of patients with Friedreich's ataxia. Eur J Clin Invest. 2001;31:1007-1011.
29. Palma A, de Carvalho M, Barata N, et al. Biochemical characterization of plasma in amyotrophic lateral sclerosis: amino acid and protein composition. Amyotroph Lateral Scler Other Motor Neuron Disord. 2005;6:104-110.
30. Mitchell P, Lee AJ, Rochtchina E, et al. Open-angle glaucoma and systemic hypertension: the blue mountains eye study. J Glaucoma. 2004;3:319-326.
31. Kincade PW, Zheng Z, Katoh S, et al. The importance of cellular environment to function of the CD44 matrix receptor. Curr Opin Cell Biol. 1997;9:635-642.
32. Aruffo A. CD44: one ligand, two functions. J Clin Invest. 1996;98:2191-2192.
33. Gasbarri A, Del Prete F, Girnita L, et al. CD44s adhesive function spontaneous and PMA-inducible CD44 cleavage are regulated at post-translational level in cells of melanocytic lineage. Melanoma Res. 2003;3:325-337.
34. Kawano Y, Okamoto I, Murakami D, et al. Ras oncoprotein induces CD44 cleavage through phosphoinositide 3-OH kinase and the rho family of small G proteins. J Biol Chem. 2000;275:29628-29635.
35. Folkman J. Role of angiogenesis in tumor growth and metastasis. Semin Oncol. 2002;29:15-18.
36. Indraccolo S. Undermining tumor angiogenesis by gene therapy: an emerging field. Curr Gene Ther. 2004;4:297-308.
37. Liu N, Lapcevich RK, Underhill CB, et al. Metastatin: a hyaluronan-binding complex from cartilage that inhibits tumor growth. Cancer Res. 2001;61:1022-1028.
38. Xu XM, Chen Y, Chen J, et al. A peptide with three hyaluronan binding motifs inhibits tumor growth and induces apoptosis. Cancer Res. 2003;63:5685-5690.
39. Sy MS, Guo YJ, Stamenkovic I. Inhibition of tumor growth in vivo with a soluble CD44-immunoglobulin fusion protein. J Exp Med. 1992;176:623-637.
40. Ahrens T, Sleeman JP, Schempp CM, et al. Soluble CD44 inhibits melanoma tumor growth by blocking cell surface CD44 binding to hyaluronic acid. Oncogene. 2001;20:3399-3408.
41. Liu N, Xu XM, Chen J, et al. Hyaluronan-binding peptide can inhibit tumor growth by interacting with Bcl-2. Int J Cancer. 2004;109:49-57.
42. Lakshman M, Subramaniam V, Jothy S. CD44 negatively regulates apoptosis in murine colonic epithelium via the mitochondrial pathway. Exp Mol Pathol. 2004;76:196-204.
43. Kim KS, Lee BH, Kim IS. The measurement of fibronectin concentrations in human aqueous humor. Korean J Ophthalmol. 1992;6:1-5.
44. Tripathi RC, Li J, Chan WF, et al. Aqueous humor in glaucomatous eyes contains an increased level of TGF-beta 2. Exp Eye Res. 1994;59:723-727.
45. Ozcan AA, Ozdemir N, Canataroglu A. The aqueous levels of TGF-beta2 in patients with glaucoma. Int Ophthalmol. 2004;25:19-22.
46. Dan J, Belyea D, Gertner G, et al. Plasminogen activator inhibitor-1 in the aqueous humor of patients with and without glaucoma. Arch Ophthalmol. 2005;123:220-224.
47. Maatta M, Tervahartiala T, Harju M, et al. Matrix metalloproteinases and their tissue inhibitors in aqueous humor of patients with primary open-angle glaucoma, exfoliation syndrome, and exfoliation glaucoma. J Glaucoma. 2005;14:64-69.
48. Hu DN, Ritch R. Hepatocyte growth factor is increased in the aqueous humor of glaucomatous eyes. J Glaucoma. 2001;10:152-157.
49. Hu DN, Ritch R, Liebmann J, et al. Vascular endothelial growth factor is increased in aqueous humor of glaucomatous eyes. J Glaucoma. 2002;11:406-410.
50. Maihofner C, Schlotzer-Schrehardt U, Guhring H, et al. Expression of cyclooxygenase-1 and -2 in normal and glaucomatous human eyes. Invest Ophthalmol Vis Sci. 2001;42:2616-2624.
51. Ferreira SM, Lerner SF, Brunzini R, et al. Oxidative stress markers in aqueous humor of glaucoma patients. Am J Ophthalmol. 2004;137:62-69.
52. Lip PL, Felmeden DC, Blann AD, et al. Plasma vascular endothelial growth factor, soluble VEGF receptor FLT-1, and von Willebrand factor in glaucoma. Br J Ophthalmol. 2002;86:1299-1302.
53. Golubnitschaja O, Yeghiazaryan K, Liu R, et al. Increased expression of matrix metalloproteinases in mononuclear blood cells of normal-tension glaucoma patients. J Glaucoma. 2004;13:66-72.
54. Gherghel D, Griffiths HR, Hilton EJ, et al. Systemic reduction in glutathione levels occurs in patients with primary open-angle glaucoma. Invest Ophthalmol Vis Sci. 2005;46:877-883.
55. Gherghel D, Hosking SL, Orgul S. Autonomic nervous system, circadian rhythms, and primary open-angle glaucoma. Surv Ophthalmol. 2004;49:491-508.
56. Liu F, Su Y, Li B, et al. Regulation of amyloid precursor protein (APP) phosphorylation and processing by p35/Cdk5 and p25/Cdk5. FEBS Lett. 2003;547:193-196.
57. Wang N, Chintala SK, Fini ME, et al. Activation of a tissue-specific stress response in the aqueous outflow pathway of the eye defines the glaucoma disease phenotype. Nat Med. 2001;27:304-309.
58. Zhang X, Schroeder A, Callahan EM, et al. Constitutive signalling pathway activity in trabecular meshwork cells from glaucomatous eyes. Exp Eye Res. 2006;82:968-973.
59. Miller AM, Nolan MJ, Choi J, et al. Lactate treatment causes NK-γB activation and CD44 shedding in cultured trabecular meshwork cells. Invest Ophthalmol Vis Sci. 2007;48:1615-1621.
60. Cisowski J, Loboda A, Jozkowicz A, et al. Role of heme oxygenase-1 in hydrogen peroxide-induced VEGF synthesis: effect of HO-1 knockout. Biochem Biophys Res Comm. 2005;326:670-676.
61. Tao Q, Spring SC, Terman BI. Comparison of the signaling mechanisms by which VEGF, H2O2, and phosphatase inhibitors activate endothelial cell ERK1/2 MAP-kinase. Microvasc Res. 2005;69:36-44.
62. Wang L, Chen L, Benincosa J, et al. VEGF-induced phosphorylation of Bcl-2 influences B lineage leukemic cell response to apoptotic stimuli. Leukemia. 2005;19:344-353.
63. Cicchillitti L, Fasanaro P, Biglioli P, et al. Oxidative stress induces protein phosphatase 2A-dependent dephosphorylation of the pocket proteins pRb, p107, and p130. J Biol Chem. 2003;278:19509-19517.
64. Liu Q, Hofmann PA. Protein phosphatase 2A-mediated cross-talk between p38 MAPK and ERK in apoptosis of cardiac myocytes. Am J Physiol Heart Circ Physiol. 2004;286:2204-2212.
65. Vachon E, Martin R, Plumb J, et al. CD44 is a phagocytic receptor. Blood. 2006;107:4149-4158.
66. Yu Q, Toole BP, Stamenkovic I. Induction of apoptosis of metastatic mammary carcinoma cells in vivo by disruption of tumor cell surface CD44 function. J Exp Med. 1997;186:1985-1996.
67. Clarke G, Collins RA, Leavitt BR, et al. A one-hit model of cell death in inherited neuronal degenerations. Nature. 2000;406:195-199.